Management of Congestive Heart Failure Exacerbation

Initial Assessment and Interventions

• The American College of Cardiology and the American Heart Association recommend evaluating adequacy of systemic perfusion, volume status, precipitating factors, whether the heart failure is new onset or chronic, and if it's associated with preserved or reduced ejection fraction 2
• Measure B-type natriuretic peptide (BNP) or N-terminal pro-B-type natriuretic peptide (NT-proBNP) to confirm the diagnosis when the contribution of heart failure is uncertain, as suggested by the American Heart Association 2
• Identify common precipitating factors including acute coronary syndromes/coronary ischemia, severe hypertension, atrial and ventricular arrhythmias, infections, pulmonary emboli, and renal failure, as recommended by the European Heart Society 3, 4

Fluid Management and Hemodynamic Support

• Administer intravenous loop diuretics promptly to patients with significant fluid overload, according to the American College of Cardiology and the American Heart Association 1, 2
• If the patient is already on oral loop diuretics, the initial IV dose should equal or exceed their chronic oral daily dose, as recommended by the American Heart Association 2, 5
• For patients with hypotension and evidence of hypoperfusion with elevated cardiac filling pressures, administer intravenous inotropic or vasopressor drugs to maintain systemic perfusion and preserve end-organ function, as suggested by the American College of Cardiology and the European Journal of Heart Failure 1, 7

Medication Management and Special Considerations

• Continue chronic oral therapies known to improve outcomes, such as ACE inhibitors/ARBs and beta-blockers, in most patients with reduced ejection fraction unless hemodynamically unstable, according to the American College of Cardiology 1, 5
• For patients not previously on these therapies, initiate them once stable before hospital discharge, as recommended by the American College of Cardiology 1
• Avoid routine use of intravenous inotropes in normotensive patients without evidence of decreased organ perfusion, as suggested by the American Heart Association 9

Transition to Discharge and Follow-up

• Transition from intravenous to oral diuretic therapy with careful attention to dosing and electrolyte monitoring, according to the American College of Cardiology 1
• Provide comprehensive written discharge instructions covering diet, discharge medications, activity level, follow-up appointments, and signs/symptoms that should prompt medical attention, as recommended by the American College of Cardiology and the European Journal of Heart Failure 1, 7, 8